Kalirin reduction rescues psychosis-associated behavioral deficits in APPswe/PSEN1dE9 transgenic mice

Josh M. Krivinko, Susan L. Erickson, Eric E. Abrahamson, Zachary P. Wills, Milos D. Ikonomovic, Peter Penzes, Robert A. Sweet*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Psychosis in Alzheimer's disease (AD+P) represents a distinct clinical and neurobiological AD phenotype and is associated with more rapid cognitive decline, higher rates of abnormal behaviors, and increased caregiver burden compared with AD without psychosis. On a molecular level, AD+P is associated with greater reductions in the protein kalirin, a guanine exchange factor which has also been linked to the psychotic disease, schizophrenia. In this study, we sought to determine the molecular and behavioral consequences of kalirin reduction in APPswe/PSEN1dE9 mice. We evaluated mice with and without kalirin reduction during tasks measuring psychosis-associated behaviors and spatial memory. We found that kalirin reduction in APPswe/PSEN1dE9 mice significantly attenuated psychosis-associated behavior at 12 months of age without changing spatial memory performance. The 12-month-old APPswe/PSEN1dE9 mice with reduced kalirin levels also had increased levels of the active, phosphorylated forms of p21 protein (Cdc42/Rac)–activated kinases (PAKs), which function in signaling pathways for maintenance of dendritic spine density, morphology, and function.

Original languageEnglish (US)
Pages (from-to)59-70
Number of pages12
JournalNeurobiology of Aging
StatePublished - Jun 1 2017


  • Alzheimer disease
  • Kalirin
  • Psychosis

ASJC Scopus subject areas

  • General Neuroscience
  • Aging
  • Clinical Neurology
  • Developmental Biology
  • Geriatrics and Gerontology


Dive into the research topics of 'Kalirin reduction rescues psychosis-associated behavioral deficits in APPswe/PSEN1dE9 transgenic mice'. Together they form a unique fingerprint.

Cite this